Chronopharmacology-Driven Precision Therapies for Time-Optimized Cardiometabolic Disease Management

TL;DR

This paper reviews how timing treatments according to the body's daily rhythms can improve outcomes for heart and metabolic diseases.

Contribution

It introduces chronopharmacology as a novel approach to optimize drug timing for better efficacy and fewer side effects in cardiometabolic conditions.

Findings

Aligning drug administration with circadian rhythms improves therapeutic effectiveness and reduces adverse effects.

Core clock genes and tissue-specific rhythms influence drug absorption and action in cardiometabolic diseases.

Artificial intelligence and wearable devices can tailor treatments to individual biological clocks.

Abstract

Cardiometabolic diseases such as high blood pressure, type 2 diabetes, high cholesterol, and obesity are leading causes of illness and death worldwide, affecting millions and straining healthcare systems. Traditional drug treatments often work inconsistently or cause side effects because they ignore the body’s natural daily rhythms, which control how organs function and how medications act. Chronopharmacology is an emerging approach that times treatments to these biological rhythms, making therapies more effective and safer. This review explores how circadian variations in gene expression and tissue function influence drug absorption and therapeutic responses, and how optimizing medication timing can improve clinical outcomes in patients with single or multiple cardiometabolic conditions. It also highlights innovative tools, including artificial intelligence, rhythm-guided biomarkers, and wearable devices, that help tailor treatments to individual biological clocks. By aligning therapies with the body’s natural cycles, chronopharmacology can enhance treatment effectiveness, reduce side effects, and pave the way for precision medicine that improves patient health and quality of life.

Cardiometabolic diseases, including hypertension, type 2 diabetes, dyslipidemia, and obesity, along with their cardiovascular complications, remain leading causes of morbidity and mortality worldwide, imposing significant public health, economic, and societal burdens. Conventional pharmacological therapies often show limited efficacy and increased adverse effects because they do not account for the body’s intrinsic circadian rhythms, which regulate organ function, drug absorption, and metabolism. Chronopharmacology, which aligns treatment timing with these biological rhythms, offers a strategy to enhance therapeutic outcomes. This review presents a comprehensive analysis of chronopharmacology principles applied to cardiometabolic disease management, integrating molecular, physiological, and clinical perspectives. It examines how core clock genes and tissue-specific circadian patterns influence drug action and absorption and summarizes evidence-based time-optimized interventions for hypertension, diabetes, dyslipidemia, obesity, and multimorbid patients. Furthermore, the review highlights emerging innovations, including artificial intelligence-guided dosing, circadian-biomarker-informed therapy selection, and wearable digital devices for real-time monitoring of biological rhythms. By synthesizing mechanistic and clinical insights, circadian-aligned treatment strategies are shown to improve drug efficacy, reduce adverse effects, and support the development of precision, rhythm-based therapeutics, offering a practical framework for personalized cardiometabolic disease care.

Figures